Compugen advances cancer immunotherapy trials, expects key data by early and mid-2027 with cash runway to 2029

Compugen Ltd. reported progress in its cancer immunotherapy pipeline, with the MAIA-ovarian trial fully enrolled and results expected by Q1 2027. Partner AstraZeneca's Phase 3 trial for rilvegostomig is anticipated to yield high-level results in H2 2027. The company also introduced UnigenX™, expanding its AI-driven discovery into tumor-targeted therapies. With a cash runway extending into 2029, Compugen is positioned to continue advancing its clinical programs and pipeline development through 2027.

AstraZeneca, Compugen's partner in cancer immunotherapy trials, is trading at USD 189.98 on Pluang, showing a 1.90% increase in the last day. This data is current as of Nov 09, 2026 19:02 WIB.